A US-based KOL assesses trends in the CML treatment landscape with an analysis of current treatment options in light of widespread tyrosine kinase inhibitor adoption. This interview also covers the unmet needs within the indication as well as assessment of breakthrough therapies in clinal trials.

This interview was conducted on February 12, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.